DOCSLIB.ORG

Mouse Pdap1 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

https://www.alphaknockout.com Mouse Pdap1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Pdap1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Pdap1 gene (NCBI Reference Sequence: NM_001033313 ; Ensembl: ENSMUSG00000029623 ) is located on Mouse chromosome 5. 6 exons are identified, with the ATG start codon in exon 1 and the TAA stop codon in exon 6 (Transcript: ENSMUST00000031627). Exon 2~3 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Pdap1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-327C12 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 2 starts from about 2.58% of the coding region. The knockout of Exon 2~3 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 2973 bp, and the size of intron 3 for 3'-loxP site insertion: 2084 bp. The size of effective cKO region: ~2429 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 6 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Pdap1 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. It may be difficult to construct this targeting vector. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(8929bp) | A(23.22% 2073) | C(24.26% 2166) | T(26.9% 2402) | G(25.62% 2288) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. Significant high GC-content regions are found. It may be difficult to construct this targeting vector. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr5 - 145137244 145140243 3000 browser details YourSeq 56 2896 2973 3000 85.8% chr6 - 22440582 22440652 71 browser details YourSeq 55 2895 2976 3000 86.7% chr5 + 140729360 140729434 75 browser details YourSeq 52 2243 2429 3000 88.3% chr11 - 102077427 102077614 188 browser details YourSeq 51 2900 2973 3000 83.7% chr14 - 76000237 76000302 66 browser details YourSeq 51 2344 2453 3000 91.9% chr13 - 37656212 37864311 208100 browser details YourSeq 50 1714 1767 3000 98.2% chr8 - 35259170 35259244 75 browser details YourSeq 50 1711 1766 3000 96.4% chr1 + 134068804 134068867 64 browser details YourSeq 48 2347 2431 3000 85.3% chr12 - 105641582 105641667 86 browser details YourSeq 47 2357 2431 3000 88.6% chr16 - 96212509 96212584 76 browser details YourSeq 45 2896 2983 3000 96.0% chr2 + 117109805 117109897 93 browser details YourSeq 45 2339 2431 3000 84.0% chr14 + 17953662 17953752 91 browser details YourSeq 45 2347 2433 3000 94.2% chr11 + 88134139 88134226 88 browser details YourSeq 45 1714 1766 3000 96.1% chr1 + 30419739 30419801 63 browser details YourSeq 42 2896 2950 3000 80.9% chr12 - 91701503 91701551 49 browser details YourSeq 42 2896 2951 3000 79.6% chr13 + 25004786 25004834 49 browser details YourSeq 41 2896 2949 3000 80.9% chr10 - 41957090 41957137 48 browser details YourSeq 41 2896 2941 3000 90.7% chr11 + 95921015 95921058 44 browser details YourSeq 40 2896 2940 3000 90.5% chr11 + 103914651 103914693 43 browser details YourSeq 40 2357 2419 3000 91.7% chr10 + 83724880 83724943 64 Note: The 3000 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr5 - 145131815 145134814 3000 browser details YourSeq 163 1278 1485 3000 90.2% chr15 - 83335785 83335989 205 browser details YourSeq 163 1277 1570 3000 91.9% chr7 + 64009529 64010147 619 browser details YourSeq 160 1271 1463 3000 92.1% chr8 + 95773667 95773861 195 browser details YourSeq 158 1277 1462 3000 90.2% chr18 + 38173398 38173579 182 browser details YourSeq 158 1277 1472 3000 93.1% chr10 + 18399385 18399894 510 browser details YourSeq 156 1277 1463 3000 90.5% chr5 - 27347300 27347479 180 browser details YourSeq 156 1276 1463 3000 89.2% chr11 - 101715075 101715258 184 browser details YourSeq 155 1276 1463 3000 89.7% chr18 - 23978155 23978339 185 browser details YourSeq 155 1279 1463 3000 91.9% chr12 - 85989400 85989584 185 browser details YourSeq 155 1279 1463 3000 93.3% chr1 - 191948241 191948433 193 browser details YourSeq 154 1278 1463 3000 92.8% chr19 + 30240868 30241054 187 browser details YourSeq 154 1278 1463 3000 91.9% chr15 + 99836212 99836397 186 browser details YourSeq 154 1277 1463 3000 91.4% chr12 + 59263902 59264091 190 browser details YourSeq 154 1277 1462 3000 89.6% chr10 + 117713896 117714077 182 browser details YourSeq 154 1259 1462 3000 86.7% chr1 + 58243337 58243525 189 browser details YourSeq 153 1277 1462 3000 91.2% chr8 - 91179849 91180033 185 browser details YourSeq 153 1287 1463 3000 93.3% chr17 - 28656180 28656356 177 browser details YourSeq 153 1277 1463 3000 90.0% chr16 - 35419879 35420061 183 browser details YourSeq 153 1277 1463 3000 92.3% chr15 - 81350202 81350396 195 Note: The 3000 bp section downstream of Exon 3 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Pdap1 PDGFA associated protein 1 [ Mus musculus (house mouse) ] Gene ID: 231887, updated on 12-Aug-2019 Gene summary Official Symbol Pdap1 provided by MGI Official Full Name PDGFA associated protein 1 provided by MGI Primary source MGI:MGI:2448536 See related Ensembl:ENSMUSG00000029623 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as PAP; PAP1; HASPP28 Expression Ubiquitous expression in CNS E11.5 (RPKM 51.8), CNS E14 (RPKM 32.2) and 28 other tissues See more Orthologs human all Genomic context Location: 5; 5 G2 See Pdap1 in Genome Data Viewer Exon count: 6 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 5 NC_000071.6 (145128770..145140025, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 5 NC_000071.5 (145889639..145900958, complement) Chromosome 5 - NC_000071.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 5 transcripts Gene: Pdap1 ENSMUSG00000029623 Description PDGFA associated protein 1 [Source:MGI Symbol;Acc:MGI:2448536] Gene Synonyms HASPP28, PAP1 Location Chromosome 5: 145,128,769-145,140,238 reverse strand. GRCm38:CM000998.2 About this gene This gene has 5 transcripts (splice variants), 207 orthologues and is a member of 1 Ensembl protein family. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Pdap1- ENSMUST00000031627.8 2353 181aa ENSMUSP00000031627.8 Protein coding CCDS39384 B2RTB0 Q3UHX2 TSL:1 201 GENCODE basic APPRIS P1 Pdap1- ENSMUST00000199218.1 2452 No protein - Retained intron - - TSL:NA 205 Pdap1- ENSMUST00000143439.1 676 No protein - Retained intron - - TSL:2 203 Pdap1- ENSMUST00000148781.1 448 No protein - Retained intron - - TSL:2 204 Pdap1- ENSMUST00000123111.7 1017 No protein - lncRNA - - TSL:1 202 Page 6 of 8 https://www.alphaknockout.com 31.47 kb Forward strand 145.12Mb 145.13Mb 145.14Mb 145.15Mb Genes Arpc1b-201 >protein coding Bud31-207 >protein coding (Comprehensive set... Arpc1b-204 >lncRNA Arpc1b-205 >protein coding Bud31-202 >retained introBnud31-204 >retained intron Arpc1b-202 >retained intron Arpc1b-203 >retained intron Bud31-206 >protein coding Arpc1b-211 >protein coding Bud31-201 >protein coding Arpc1b-209 >protein coding Arpc1b-207 >lncRNA Bud31-203 >protein coding Arpc1b-206 >retained intron Bud31-205 >retained intron Arpc1b-208 >protein coding Arpc1b-210 >retained intron Contigs AC110556.15 > < AC127411.3 Genes (Comprehensive set... < Pdap1-201protein coding < Ptcd1-201protein coding < Pdap1-202lncRNA < Pdap1-203retained intron < Pdap1-204retained intron < Pdap1-205retained intron Regulatory Build 145.12Mb 145.13Mb 145.14Mb 145.15Mb Reverse strand 31.47 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding Ensembl protein coding merged Ensembl/Havana Non-Protein Coding processed transcript RNA gene Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000031627 < Pdap1-201protein coding Reverse strand 11.47 kb ENSMUSP00000031... MobiDB lite Low complexity (Seg) Coiled-coils (Ncoils) Pfam Casein kinase substrate, phosphoprotein PP28 PANTHER 28kDa heat- and acid-stable phosphoprotein PTHR22055:SF5 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend synonymous variant Scale bar 0 20 40 60 80 100 120 140 160 181 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Recommended publications
  • Identification of Novel Pathways That Promote Anoikis Through Genome-Wide Screens

    Identification of Novel Pathways That Promote Anoikis Through Genome-Wide Screens

    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2016-10-14 Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens Victoria E. Pedanou University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Biology Commons, and the Cancer Biology Commons Repository Citation Pedanou VE. (2016). Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens. GSBS Dissertations and Theses. https://doi.org/10.13028/M27G6D. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/889 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. i TITLE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY OCTOBER 14TH, 2016 CANCER BIOLOGY ii SIGNATURE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU This work was undertaken in the Graduate School of Biomedical Sciences Cancer Biology The signature of the Thesis Advisor signifies validation of Dissertation content ___________________________ Michael R. Green, Thesis Advisor The signatures of the Dissertation Defense Committee signify completion and approval as to style and content of the Dissertation __________________________________ Eric H.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors

    Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors

    University of Cincinnati Date: 12/20/2010 I, Arturo R Maldonado , hereby submit this original work as part of the requirements for the degree of Doctor of Philosophy in Developmental Biology. It is entitled: Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors Student's name: Arturo R Maldonado This work and its defense approved by: Committee chair: Jeffrey Whitsett Committee member: Timothy Crombleholme, MD Committee member: Dan Wiginton, PhD Committee member: Rhonda Cardin, PhD Committee member: Tim Cripe 1297 Last Printed:1/11/2011 Document Of Defense Form Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors A dissertation submitted to the Graduate School of the University of Cincinnati College of Medicine in partial fulfillment of the requirements for the degree of DOCTORATE OF PHILOSOPHY (PH.D.) in the Division of Molecular & Developmental Biology 2010 By Arturo Rafael Maldonado B.A., University of Miami, Coral Gables, Florida June 1993 M.D., New Jersey Medical School, Newark, New Jersey June 1999 Committee Chair: Jeffrey A. Whitsett, M.D. Advisor: Timothy M. Crombleholme, M.D. Timothy P. Cripe, M.D. Ph.D. Dan Wiginton, Ph.D. Rhonda D. Cardin, Ph.D. ABSTRACT Since 1999, cancer has surpassed heart disease as the number one cause of death in the US for people under the age of 85. Malignant Peripheral Nerve Sheath Tumor (MPNST), a common malignancy in patients with Neurofibromatosis, and colorectal cancer are midkine- producing tumors with high mortality rates. In vitro and preclinical xenograft models of MPNST were utilized in this dissertation to study the role of midkine (MDK), a tumor-specific gene over- expressed in these tumors and to test the efficacy of a MDK-transcriptionally targeted oncolytic HSV-1 (oHSV).
  • Version 1; Peer Review: 1 Approved, 1 Approved with Reservations]

    Version 1; Peer Review: 1 Approved, 1 Approved with Reservations]

    F1000Research 2021, 10:330 Last updated: 26 AUG 2021 METHOD ARTICLE A signaling pathway-driven bioinformatics pipeline for predicting therapeutics against emerging infectious diseases [version 1; peer review: 1 approved, 1 approved with reservations] Tiana M. Scott , Sam Jensen, Brett E. Pickett Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, 84602, USA v1 First published: 29 Apr 2021, 10:330 Open Peer Review https://doi.org/10.12688/f1000research.52412.1 Latest published: 20 Aug 2021, 10:330 https://doi.org/10.12688/f1000research.52412.2 Reviewer Status Invited Reviewers Abstract Background: Severe acute respiratory syndrome coronavirus-2 (SARS- 1 2 CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), is a novel Betacoronavirus that was first reported in Wuhan, China in version 2 December of 2019. The virus has since caused a worldwide pandemic (revision) that highlights the need to quickly identify potential prophylactic or 20 Aug 2021 therapeutic treatments that can reduce the signs, symptoms, and/or spread of disease when dealing with a novel infectious agent. To version 1 combat this problem, we constructed a computational pipeline that 29 Apr 2021 report report uniquely combines existing tools to predict drugs and biologics that could be repurposed to combat an emerging pathogen. 1. José Pedro Cerón-Carrasco , UCAM Methods: Our workflow analyzes RNA-sequencing data to determine differentially expressed genes, enriched Gene Ontology (GO) terms, Catholic University of Murcia, Murcia, Spain and dysregulated pathways in infected cells, which can then be used to identify US Food and Drug Administration (FDA)-approved drugs 2. Babatunde Joseph Oso , McPherson that target human proteins within these pathways.
  • Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss

    Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss

    cells Review Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss 1, 1, 1 1,2,3 1 Gayle B. Collin y, Navdeep Gogna y, Bo Chang , Nattaya Damkham , Jai Pinkney , Lillian F. Hyde 1, Lisa Stone 1 , Jürgen K. Naggert 1 , Patsy M. Nishina 1,* and Mark P. Krebs 1,* 1 The Jackson Laboratory, Bar Harbor, Maine, ME 04609, USA; [email protected] (G.B.C.); [email protected] (N.G.); [email protected] (B.C.); [email protected] (N.D.); [email protected] (J.P.); [email protected] (L.F.H.); [email protected] (L.S.); [email protected] (J.K.N.) 2 Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand 3 Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand * Correspondence: [email protected] (P.M.N.); [email protected] (M.P.K.); Tel.: +1-207-2886-383 (P.M.N.); +1-207-2886-000 (M.P.K.) These authors contributed equally to this work. y Received: 29 February 2020; Accepted: 7 April 2020; Published: 10 April 2020 Abstract: Inherited retinal degeneration (RD) leads to the impairment or loss of vision in millions of individuals worldwide, most frequently due to the loss of photoreceptor (PR) cells. Animal models, particularly the laboratory mouse, have been used to understand the pathogenic mechanisms that underlie PR cell loss and to explore therapies that may prevent, delay, or reverse RD. Here, we reviewed entries in the Mouse Genome Informatics and PubMed databases to compile a comprehensive list of monogenic mouse models in which PR cell loss is demonstrated.
  • Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands That Promote Axonal Growth

    Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands That Promote Axonal Growth

    Research Article: New Research Development Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands that Promote Axonal Growth Jeremy S. Toma,1 Konstantina Karamboulas,1,ª Matthew J. Carr,1,2,ª Adelaida Kolaj,1,3 Scott A. Yuzwa,1 Neemat Mahmud,1,3 Mekayla A. Storer,1 David R. Kaplan,1,2,4 and Freda D. Miller1,2,3,4 https://doi.org/10.1523/ENEURO.0066-20.2020 1Program in Neurosciences and Mental Health, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada, 2Institute of Medical Sciences University of Toronto, Toronto, Ontario M5G 1A8, Canada, 3Department of Physiology, University of Toronto, Toronto, Ontario M5G 1A8, Canada, and 4Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1A8, Canada Abstract Peripheral nerves provide a supportive growth environment for developing and regenerating axons and are es- sential for maintenance and repair of many non-neural tissues. This capacity has largely been ascribed to paracrine factors secreted by nerve-resident Schwann cells. Here, we used single-cell transcriptional profiling to identify ligands made by different injured rodent nerve cell types and have combined this with cell-surface mass spectrometry to computationally model potential paracrine interactions with peripheral neurons. These analyses show that peripheral nerves make many ligands predicted to act on peripheral and CNS neurons, in- cluding known and previously uncharacterized ligands. While Schwann cells are an important ligand source within injured nerves, more than half of the predicted ligands are made by nerve-resident mesenchymal cells, including the endoneurial cells most closely associated with peripheral axons. At least three of these mesen- chymal ligands, ANGPT1, CCL11, and VEGFC, promote growth when locally applied on sympathetic axons.
  • Comprehensive Analysis of 19Q12 Amplicon in Human Gastric Cancers

    Comprehensive Analysis of 19Q12 Amplicon in Human Gastric Cancers

    Modern Pathology (2006) 19, 854–863 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Comprehensive analysis of 19q12 amplicon in human gastric cancers Suet Yi Leung1, Coral Ho2, I-Ping Tu3, Rui Li4, Samuel So4, Kent-Man Chu5, Siu Tsan Yuen1 and Xin Chen2 1Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong; 2Department of Biopharmaceutical Sciences, University of California, San Francisco, CA, USA; 3The Institute of Statistical Science, Acdemia Sinica, Taipei, Taiwan, ROC; 4Department of Surgery, Stanford University, Stanford, CA, USA and 5Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong Amplification at 19q12 has been observed in multiple tumor types, while cyclin E1 (CCNE1) has been considered to be the key oncogene within this amplicon. We have previously applied cDNA microarray analysis to systematically characterize gene expression patterns of gastric tumor and nontumor samples. We identified a cluster of five tightly coregulated genes all located at chromosome 19q12, including CCNE1. We found that the 19q12 gene cluster is highly expressed in gastric tumors compared to nontumor gastric samples. Array based comparative genomic hybridization and real-time PCR was used to define the boundary of the 19q12 amplicon to a region of approximately 200 kb. Interestingly, we found that in some cases amplification at 19q12 was not associated with DNA copy number gain at CCNE1, suggesting that some other genes within the 19q12 amplicon may also have important function during gastric tumorigenesis. We found high expression of the 19q12 gene cluster to be statistically correlated with the cell proliferation gene signature.
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards

    Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards

    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
  • Dynamic Patterns of Histone Methylation Are Associated With

    Dynamic Patterns of Histone Methylation Are Associated With

    Molecular Pharmacology Fast Forward. Published on February 2, 2009 as doi:10.1124/mol.108.052993 MOL #52993 Dynamic Patterns of Histone Methylation are Associated with Ontogenic Expression of the Cyp3a Genes during Mouse Liver Maturation Ye Li, Yue Cui, Steven N. Hart, Curtis D. Klaassen, and Xiao-bo Zhong Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA. 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. MOL #52993 Running title: Epigenetic control of Cyp3a expression in liver maturation Corresponding author: Dr. Xiao-bo Zhong, Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA. Telephone: 913-588-0401; Fax: 913-588-7501; E- mail: [email protected]. Number of text pages: 28 Number of tables: 1 Number of figures: 5 Number of references: 40 Number of words in Abstract: 243 Number of words in Introduction: 736 Number of words in Discussion: 1316 Abbreviations: CYP3A4: human cytochrome P450, family 3, subfamily A, polypeptide 4 gene; CYP3A7: human cytochrome P450, family 3, subfamily A, polypeptide 7 gene; Cyp3a11: mouse cytochrome P450, family 3, subfamily a, polypeptide 11 gene; Cyp3a16: mouse cytochrome P450, family 3, subfamily a, polypeptide 16 gene; DNAme: DNA methylation; H3K4me2: histone 3 lysine 4 dimethylation; H3K27me3: histone 3 lysine 27 trimethylation. 2 MOL #52993 Abstract Human cytochrome P450 3A members (CYP3As) are major drug-metabolizing enzymes in livers. Two genes, CYP3A4 and CYP3A7, exhibit a developmental switch in gene expression during liver maturation.
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0098188 A1 Niculescu Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2011/0098188 A1 Niculescu Et Al

    US 2011 0098188A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0098188 A1 Niculescu et al. (43) Pub. Date: Apr. 28, 2011 (54) BLOOD BOMARKERS FOR PSYCHOSIS Related U.S. Application Data (60) Provisional application No. 60/917,784, filed on May (75) Inventors: Alexander B. Niculescu, Indianapolis, IN (US); Daniel R. 14, 2007. Salomon, San Diego, CA (US) Publication Classification (51) Int. Cl. (73) Assignees: THE SCRIPPS RESEARCH C40B 30/04 (2006.01) INSTITUTE, La Jolla, CA (US); CI2O I/68 (2006.01) INDIANA UNIVERSITY GOIN 33/53 (2006.01) RESEARCH AND C40B 40/04 (2006.01) TECHNOLOGY C40B 40/10 (2006.01) CORPORATION, Indianapolis, IN (52) U.S. Cl. .................. 506/9: 435/6: 435/7.92; 506/15; (US) 506/18 (57) ABSTRACT (21) Appl. No.: 12/599,763 A plurality of biomarkers determine the diagnosis of psycho (22) PCT Fled: May 13, 2008 sis based on the expression levels in a sample Such as blood. Subsets of biomarkers predict the diagnosis of delusion or (86) PCT NO.: PCT/US08/63539 hallucination. The biomarkers are identified using a conver gent functional genomics approach based on animal and S371 (c)(1), human data. Methods and compositions for clinical diagnosis (2), (4) Date: Dec. 22, 2010 of psychosis are provided. Human blood Human External Lines Animal Model External of Evidence changed in low vs. high Lines of Evidence psychosis (2pt.) Human postmortem s Animal model brai brain data (1 pt.) > Cite go data (1 p. Biomarker For Bonus 1 pt. Psychosis Human genetic 2 N linkage? association A all model blood data (1 pt.) data (1 p.

  • Gene Expression in Sheep Carotid Arteries: Major Changes with Maturational Development

    nature publishing group Basic Science Investigation Articles Gene expression in sheep carotid arteries: major changes with maturational development Ravi Goyal1 and Lawrence D. Longo1 BACKGROUND: With development from immature fetus to individual. In these few moments of parturition, the central near-term fetus, newborn, and adult, the cerebral vasculature circulatory pattern must change from one based on placental undergoes a number of fundamental changes. Although the transfer of respiratory gases to one based on pulmonary ven- near-term fetus is prepared for a transition from an intra- to tilation. Systemic vascular resistance increases dramatically, as extra-uterine existence, this is not necessarily the case with the does arterial blood pressure, while pulmonary vascular resis- premature fetus, which is more susceptible to cerebrovascu- tance and pressure fall. Cardiac (i.e., left-ventricular) output lar dysregulation. In this study, we tested the hypothesis that initially increases and then slowly decreases over succeeding the profound developmental and age-related differences in days. Despite these dramatic changes in cardiac function and cerebral blood flow are associated with significant underlying vascular resistance, blood flow to the brain increases only changes in gene expression. slightly to maintain optimal cerebral oxygenation and metabo- METHODS: With the use of oligonucleotide microarray and lism (4). In addition to the cerebral vasculature, per se, carotid pathway analysis, we elucidated significant changes in the arteries (CAs) play a crucial role in maintaining optimal CBF transcriptome with development in sheep carotid arteries. (5). Studies have demonstrated a significant pressure gradi- RESULTS: As compared with adult, we demonstrate a ent from CAs to cerebral arteries (6), probably to minimize U-shaped relationship of gene expression in major cerebro- the exposure of high pressure to delicate cerebral arteries, and vascular network/pathways during early life, e.g., the level of underscore the importance of CAs in the regulation of CBF.

  • Platelet-Derived Growth Factor Receptor Alpha Signaling Pathways in Development and Liver Disease

    Platelet-derived growth factor receptor alpha signaling pathways in development and liver disease Brian J. Hayes A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2014 Reading Committee: Jean Campbell, Chair Daniel Bowen-Pope William Mahoney Jr. Program Authorized to Offer Degree: Pathology ©Copyright 2014 Brian J. Hayes University of Washington Abstract Platelet-derived growth factor receptor alpha signaling pathways in development and liver disease Brian J. Hayes Chair of the Supervisory Committee: Jean S. Campbell, Assistant Professor Department of Pathology Platelet derived growth factor receptor alpha (PDGFR α) signaling is critical for development and disease. Insufficient PDGFR α signal transduction results in developmental anomolies, while excessive signaling results in fibrosis and carcinogenesis. PDGFR α signal transduction is regulated at multiple levels, two of which are ligand binding and Pdgfr α expression levels. In my thesis work, I describe a Pdgfc mutant mouse, Pdgfc tm1Lex , in which only growth factor coding exons are deleted. Viability of Pdgfc tm1Lex mice, which express only the complement components C1r/C1s, sea urchin EGF, bone morphogenetic protein 1 (CUB) domain of PDGF- C, depends on the presence of both Pdgfr α alleles. Alternative splicing in Pdgfc tm1Lex mice gives rise to a truncated transcript that contains the entire coding region of the CUB domain of PDGF- C, but lacks the majority of the exons encoding the growth factor domain (GFD). Contrary to Pdgfc knockout (KO) mice, Pdgfc tm1Lex mice are viable, suggesting that the CUB domain of PDGF-C contributes to PDGFR α signal transduction.